Sihuan Pharmaceutical Holdings Group Management
Management criteria checks 3/4
Sihuan Pharmaceutical Holdings Group's CEO is Weicheng Guo, appointed in Oct 2014, has a tenure of 9.58 years. total yearly compensation is CN¥3.15M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth HK$6.47M. The average tenure of the management team and the board of directors is 1.6 years and 8.2 years respectively.
Key information
Weicheng Guo
Chief executive officer
CN¥3.2m
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 9.6yrs |
| CEO ownership | 0.1% |
| Management average tenure | 1.6yrs |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05
Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) A Risky Dividend Stock?
Jul 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -CN¥54m |
| Jun 30 2023 | n/a | n/a | -CN¥2b |
| Mar 31 2023 | n/a | n/a | -CN¥2b |
| Dec 31 2022 | CN¥3m | CN¥3m | -CN¥2b |
| Jun 30 2022 | n/a | n/a | -CN¥144m |
| Mar 31 2022 | n/a | n/a | CN¥141m |
| Dec 31 2021 | CN¥6m | CN¥6m | CN¥427m |
| Sep 30 2021 | n/a | n/a | CN¥681m |
| Jun 30 2021 | n/a | n/a | CN¥945m |
| Mar 31 2021 | n/a | n/a | CN¥727m |
| Dec 31 2020 | CN¥6m | CN¥6m | CN¥508m |
| Sep 30 2020 | n/a | n/a | -CN¥14m |
| Jun 30 2020 | n/a | n/a | -CN¥537m |
| Mar 31 2020 | n/a | n/a | -CN¥2b |
| Dec 31 2019 | CN¥6m | CN¥6m | -CN¥3b |
| Sep 30 2019 | n/a | n/a | -CN¥2b |
| Jun 30 2019 | n/a | n/a | -CN¥1b |
| Mar 31 2019 | n/a | n/a | CN¥238m |
| Dec 31 2018 | CN¥6m | CN¥6m | CN¥2b |
| Sep 30 2018 | n/a | n/a | CN¥1b |
| Jun 30 2018 | n/a | n/a | CN¥1b |
| Mar 31 2018 | n/a | n/a | CN¥1b |
| Dec 31 2017 | CN¥6m | CN¥6m | CN¥1b |
Compensation vs Market: Weicheng's total compensation ($USD435.02K) is about average for companies of similar size in the Hong Kong market ($USD485.88K).
Compensation vs Earnings: Weicheng's compensation has been consistent with company performance over the past year.
CEO
Weicheng Guo (59 yo)
9.6yrs
Tenure
CN¥3,150,000
Compensation
Dr. Weicheng Guo co-founded Sihuan Pharmaceutical Holdings Group Ltd. and has been its Chief Executive Officer since October 20, 2014. Dr. Guo is responsible for the overall operations of Sihuan Pharmaceut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 18yrs | CN¥7.00m | 5.36% CN¥ 283.5m | |
| Deputy Chairman & CEO | 9.6yrs | CN¥3.15m | 0.12% CN¥ 6.5m | |
| Deputy CEO | 1.6yrs | CN¥3.50m | no data | |
| Executive Director | no data | CN¥742.00k | 2.14% CN¥ 113.4m | |
| Joint Company Secretary & Executive Director | 1.6yrs | CN¥1.80m | no data | |
| Joint Company Secretary | 1.6yrs | no data | no data | |
| Deputy General Manager | no data | CN¥4.26m | no data |
1.6yrs
Average Tenure
59yo
Average Age
Experienced Management: 460's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 18yrs | CN¥7.00m | 5.36% CN¥ 283.5m | |
| Deputy Chairman & CEO | 18yrs | CN¥3.15m | 0.12% CN¥ 6.5m | |
| Deputy CEO | 1.6yrs | CN¥3.50m | no data | |
| Executive Director | 6.1yrs | CN¥742.00k | 2.14% CN¥ 113.4m | |
| Joint Company Secretary & Executive Director | 6.1yrs | CN¥1.80m | no data | |
| Independent Non-Executive Director | 10.7yrs | CN¥462.00k | no data | |
| Independent Non-Executive Director | 10.3yrs | CN¥462.00k | no data | |
| Independent Non-Executive Director | 1.1yrs | no data | no data |
8.2yrs
Average Tenure
60yo
Average Age
Experienced Board: 460's board of directors are considered experienced (8.2 years average tenure).